US20220220522A1 - Method for producing anhydrous galactose derived from seaweed - Google Patents
Method for producing anhydrous galactose derived from seaweed Download PDFInfo
- Publication number
- US20220220522A1 US20220220522A1 US17/586,649 US202217586649A US2022220522A1 US 20220220522 A1 US20220220522 A1 US 20220220522A1 US 202217586649 A US202217586649 A US 202217586649A US 2022220522 A1 US2022220522 A1 US 2022220522A1
- Authority
- US
- United States
- Prior art keywords
- ahg
- agarose
- acid
- agar
- agarobiose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 31
- 229930182830 galactose Natural products 0.000 title abstract description 15
- 241001474374 Blennius Species 0.000 title abstract description 3
- 229920000936 Agarose Polymers 0.000 claims abstract description 49
- 229920001817 Agar Polymers 0.000 claims abstract description 45
- 239000008272 agar Substances 0.000 claims abstract description 45
- JPLATTLXZFUKRQ-UHFFFAOYSA-N Agarobiose Natural products OCC1OC(OC2C(O)COC2C(O)C=O)C(O)C(O)C1O JPLATTLXZFUKRQ-UHFFFAOYSA-N 0.000 claims abstract description 37
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 34
- 239000007795 chemical reaction product Substances 0.000 claims description 29
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 27
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 claims description 16
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- WZYRMLAWNVOIEX-MOJAZDJTSA-N (2s)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyacetaldehyde Chemical compound O=C[C@@H](O)[C@@H]1OC[C@H](O)[C@H]1O WZYRMLAWNVOIEX-MOJAZDJTSA-N 0.000 abstract description 71
- 239000002253 acid Substances 0.000 abstract description 28
- 244000005700 microbiome Species 0.000 abstract description 21
- 238000005903 acid hydrolysis reaction Methods 0.000 abstract description 17
- 238000006386 neutralization reaction Methods 0.000 abstract description 13
- 238000000746 purification Methods 0.000 abstract description 11
- DCQFFOLNJVGHLW-UHFFFAOYSA-N 4'-Me ether-Punctatin+ Natural products O1C(O)C(O)C2OCC1C2O DCQFFOLNJVGHLW-UHFFFAOYSA-N 0.000 abstract description 10
- WZYRMLAWNVOIEX-UHFFFAOYSA-N cinnamtannin B-2 Natural products O=CC(O)C1OCC(O)C1O WZYRMLAWNVOIEX-UHFFFAOYSA-N 0.000 abstract description 10
- 230000007071 enzymatic hydrolysis Effects 0.000 abstract description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 abstract description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract 1
- 239000000758 substrate Substances 0.000 description 27
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 26
- 108090000604 Hydrolases Proteins 0.000 description 21
- 102000004157 Hydrolases Human genes 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000010306 acid treatment Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 108010046109 neoagarobiose hydrolase Proteins 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- JWMBOBQNPBCYER-UHFFFAOYSA-N 4-[(4,8-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl)oxy]-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound OC1C(CO)OC(O)C(O)C1OC1C(O)C(C2O)OCC2O1 JWMBOBQNPBCYER-UHFFFAOYSA-N 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000000413 hydrolysate Substances 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241001170685 Saccharophagus degradans 2-40 Species 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000006912 hydrolase reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- 241001670248 Saccharophagus degradans Species 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000588901 Zymomonas Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- TVUDDKFHNCHGDW-UHFFFAOYSA-N acetic acid trihydrochloride Chemical compound Cl.Cl.Cl.CC(O)=O TVUDDKFHNCHGDW-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 230000000543 agarolytic effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000000120 microwave digestion Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- XOOMNEFVDUTJPP-UHFFFAOYSA-N naphthalene-1,3-diol Chemical compound C1=CC=CC2=CC(O)=CC(O)=C21 XOOMNEFVDUTJPP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
Definitions
- the present invention relates to a method of producing anhydrous galactose derived from seaweed, in which the production yield of 3,6-anhydro-L-galactose is enhanced using a microorganism in a purification process after acid treatment, neutralization, and enzymatic hydrolysis of agarose or agar.
- a major polysaccharide constituting red algae is agarose
- agarose is a polymer in which 3,6-anhydro-L-galactose (hereinafter, referred to as “AHG”) and D-galactose are alternately bound via ⁇ -1,3 linkage and ⁇ -1,4 linkage.
- AHG is a multifunctional high-value-added material having an anticariogenic function and a colorectal cancer prevention function as well as cosmetic whitening and moisturizing functions. Therefore, it is very important to efficiently produce AHG from agar or agarose, which is the main carbohydrate of red algae, and efficiently purify AHG.
- Methods of producing AHG are as follows. First, there is a method of producing AHG by hydrolyzing agarose or agar using a strong acid at a high temperature. This method is inexpensive and simple, but disadvantageous in that AHG and D-galactose, which are monosaccharides, are decomposed into 5-hydroxymethyl furfural (5-HMF) at high temperatures, resulting in a reduced AHG production yield. Second, there is a method of producing AHG by hydrolyzing agarose or agar using an enzyme at room temperature.
- 5-HMF 5-hydroxymethyl furfural
- agarose or agar is decomposed into agarooligosaccharides (AOSs) using a weak acid such as acetic acid, and then the AOSs are produced as neoagarobiose (NAB) through an enzymatic reaction of exo-type ⁇ -agarase II.
- AOSs agarooligosaccharides
- NAB neoagarobiose
- agarotriose is produced as a by-product, and it is necessary to introduce an additional enzyme called agarolytic ⁇ -galactosidase (ABG) in order to decompose the agarotriose.
- ABSG agarolytic ⁇ -galactosidase
- AHG and D-galactose which are monosaccharides, may be obtained through an enzymatic reaction of neoagarobiose hydrolase (NABH).
- NABH neoagarobiose hydrolase
- An object of the present invention is to provide a method of producing agarobiose from agarose or agar through strong acid treatment and neutralization.
- Another object of the present invention is to provide a method of producing 3,6-anhydro-L-galactose through anaerobic and aerobic culturing of a microorganism with agarose or agar having undergone strong acid treatment, neutralization, and enzymatic hydrolysis.
- the present invention provides a method of producing agarobiose, including allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, in which a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w).
- the present invention also provides a method of producing 3,6-anhydro-L-galactose, including: a step of allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w);
- AHG is obtained without a separate existing purification process through established optimum conditions capable of producing a high concentration of agarobiose by treatment of agarose or agar with a strong acid and neutralization thereof, and through culturing of an enzyme using agarobiose as a substrate and a microorganism using galactose as a substrate, and thus AHG loss can be reduced, thus providing an effect of obtaining AHG with a high yield.
- FIG. 1 is a schematic diagram illustrating production of AHG from agarose or agar and purification thereof, wherein A diagram inserted within the FIG. 1 illustrates a process of producing AHG through conventional enzyme saccharification and purifying AHG using a microorganism, and B diagram inserted within the FIG. 1 illustrates an AHG production process of the present invention.
- FIG. 3 a illustrates TLC analysis results of a reaction product obtained by treating agarose with 0.5% (w/v), 1% (w/v), or 2% (w/v) phosphoric acid, followed by acid hydrolysis at 110° C. for 10 minutes according to the AHG production process of the present invention.
- FIG. 3 b illustrates GC-TOF/MS analysis results of a reaction product obtained by treating agarose with 2% (w/v) phosphoric acid, followed by acid hydrolysis at 110° C. for 10 minutes according to the AHG production process of the present invention.
- FIG. 4 a illustrates SDS-PAGE analysis results of recombinant agarooligosaccharide hydrolase.
- FIG. 4 b is a TLC image showing a reaction product obtained by reacting agar or agarose having undergone acid treatment and neutralization with the agarooligosaccharide hydrolase.
- FIG. 4 c illustrates GC-TOF/MS analysis results of a reaction product obtained by reacting agar or agarose having undergone acid treatment and neutralization with the agarooligosaccharide hydrolase.
- FIG. 5 is a set of TLC images showing results of confirming AHG purification using yeast, which is a GRAS microorganism, from agarose or agar, according to the AHG production process of the present invention, at different yeast culture time points.
- FIG. 6 illustrates the saccharification yield at different time points after acid hydrolysis of 20% (w/v) agar with phosphoric acid at a concentration of 1% (w/v), 2% (w/v), or 3% (w/v) at 90° C. according to the AHG production process of the present invention.
- FIG. 7 a illustrates HPLC analysis results of a reaction product obtained after treatment of agar with 1% (w/v) phosphoric acid and acid hydrolysis of the treated-agar at 90° C. for 480 minutes according to the AHG production process of the present invention.
- FIG. 7 b illustrates HPLC analysis results of a reaction product obtained after treatment of agar with 2% (w/v) phosphoric acid and acid hydrolysis of the treated-agar at 90° C. for 480 minutes according to the AHG production process of the present invention.
- FIG. 7 c illustrates HPLC analysis results of a reaction product obtained after treatment of agar with 3% (w/v) phosphoric acid and acid hydrolysis of the treated-agar at 90° C. for 480 minutes according to the AHG production process of the present invention.
- the present invention relates to a method of producing agarobiose, including: allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, in which a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w).
- the present invention also provides a method of producing 3,6-anhydro-L-galactose, including: a step of allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with phosphoric acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w);
- the inventors of the present invention established a condition of minimum production of 5-HMF even when a strong acid was used for the production of AHG and performed a pretreatment reaction on agarose or agar at a high concentration, thereby obtaining agarooligosaccharides, particularly agarobiose with a high yield at a high concentration (see FIG. 1 ).
- the agarobiose and agarooligosaccharides obtained with a high yield at a high concentration is neutralized with a strong base, and at this time, salt produced through neutralization (e.g., phosphate) is not removed and used as a buffer solution in the next step, i.e., the agarooligosaccharide hydrolase reaction.
- salt produced through neutralization e.g., phosphate
- AHG and D-galactose are produced at high concentrations using agarooligosaccharide hydrolase, which efficiently degrades agarobiose.
- AHG is purified using yeast, which is generally recognized as a safe (GRAS) microorganism for humans.
- the concentration of the strong acid used in the strong acid treatment of agarose or agar may range from 0.1% (w/v) to 5% (w/v), more particularly 0.5% (w/v) to 3% (w/v).
- concentration of the strong acid is within the above range, the production of 5-HMF by strong acid treatment of agarose or agar may be minimized, and at the same time, a high concentration of agarobiose may be produced, and thus the production of AHG with a high yield is possible.
- the strong acid may be phosphoric acid, sulfuric acid, hydrochloric acid, nitric acid, or the like. More specifically, the strong acid may be phosphoric acid.
- agarooligosaccharides including a high concentration of agarobiose may be produced.
- the strong acid-treated agarose or agar is neutralized to a pH of 5 to 7 by adding a strong base thereto.
- NaOH, KOH, Ca(OH) 2 , Ba(OH) 2 , or the like may be used, but the present invention is not limited thereto.
- the agarooligosaccharide hydrolase is an enzyme that decomposes agarobiose as a substrate into D-galactose and 3,6-anhydro-L-galactose, and may include the amino acid sequences set forth in SEQ ID NO: 1.
- the agarooligosaccharide hydrolase may be transcribed and translated through a DNA segment, i.e., a coding gene, involved in producing a polypeptide including an intervening sequence between individual coding segments as well as a region before and after the coding region of the enzyme.
- agarooligosaccharide hydrolase may be transcribed and translated from the sequences set forth in SEQ ID NO: 2, but is not particularly limited thereto.
- mutant proteins having one or more substitutions, deletions, dislocations, additions, or the like of the enzyme proteins having an agarobiose hydrolytic activity are also within the scope of the enzyme of the present invention.
- the agarooligosaccharide hydrolase includes an amino acid sequence with at least 80% homology, at least 85% homology, at least 90% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, and at least 99% homology to the amino acid sequences set forth in SEQ ID NO: 1.
- the agarooligosaccharide hydrolase may be derived from Saccharophagus degradans 2-40 T , but the present invention is not particularly limited thereto.
- a reaction between the agarobiose and the agarooligosaccharide hydrolase may be performed at a temperature of 20° C. to 40° C. and 100 rpm to 300 rpm for 5 hours to 48 hours. More particularly, the reaction therebetween may be performed at a temperature of 30° C. to 40° C. for 10 hours to 24 hours.
- a polypeptide having a sequence homology of a certain percentage (for example, 80%, 85%, 90%, 95%, or 99%) with respect to another sequence means that two sequences has the same amino acid residues at the above percentage upon sequence comparison when the two sequences are aligned.
- the alignment and percentage homology or identity may be determined using any suitable software program known in the related art, for example, those described in Current Protocols in Molecular Biology (F. M. Ausubel, et al., (eds) 1987 Supplement 30 section 7.7.18).
- a preferred program includes the GCG Pileup program, FASTA (Pearson, et al., 1988 Proc. Natl. Acad. Sci.
- the term “recombination” used in connection with cells, nucleic acids, proteins, or vectors indicates that the cells, nucleic acids, proteins, or vectors are modified by introduction of heterologous nucleic acids or proteins or alteration of inherent nucleic acids or proteins, or that the cells are derived from such modified cells. That is, the recombinant cells, for example, express genes which are not found in the cells in an inherent (non-recombinant) form, or express inherent genes which are expressed abnormally upon expression or not expressed at all.
- nucleic acid encompasses all types of single- or double-stranded DNAs, RNAs, and chemical variants thereof.
- nucleic acid and polynucleotide may be used interchangeably herein. Since the genetic codes are degenerate, one or more codons may be used to encode a specific amino acid, and the present invention encompasses polynucleotides encoding certain amino acid sequences.
- introduction used to describe an insertion of a nucleic acid sequence into cells refers to “transfection,” “transformation,” or “transduction,” and encompasses references to the integration of a nucleic acid sequence into eukaryotic or prokaryotic cells.
- the nucleic acid sequence is integrated into the genome (for example, a chromosome, a plasmid, a plastid, or mitochondrial DNA) of a cell, and converted into an autonomous replicon or expressed temporarily.
- agarobiose is hydrolyzed into D-galactose and AHG by the agarooligosaccharide hydrolase, which uses agarobiose as a substrate, and when a microorganism having the ability to metabolize galactose is cultured therewith under anaerobic or aerobic conditions, galactose is consumed in the microorganism culture broth, and only AHG remains. Therefore, there is no need to go through an additional process of separately purifying AHG from a hydrolysate including galactose and AHG.
- the microorganism having the ability to metabolize galactose may be any one of: lactic acid bacteria including Bifidobacterium and Lactobacillus such as L. casei, L. acidophilus, L. bulgaricus, B. longum, B. bifidum, Actiregularis , and the like; Bacillus; Streptomyces; Corynebacterium; Zymomonas such as Z. mobilis and the like; Escherichia coli ; and yeasts such as Saccharomyces cerevisiae, Pichia pastoris , and the like.
- Bifidobacterium and Lactobacillus such as L. casei, L. acidophilus, L. bulgaricus, B. longum, B. bifidum, Actiregularis , and the like
- Bacillus Streptomyces
- Corynebacterium Corynebacterium
- Zymomonas such as Z. mobilis and the
- the amount of substrate added was optimized. 16.8% (w/v), 23.8% (w/v), 30.7% (w/v), or 36.8% (w/v) of an agarose substrate was subjected to acid hydrolysis using 0.5% (w/v) phosphoric acid at 140° C. for 10 minutes. At this time, the amount of used agarose is based on a dry weight. The degree of liquefaction was expressed as a percentage of a value obtained by subtracting, from an initial weight (g) of agarose added, the amount (g) of precipitate dried at 105° C. for 12 hours after having undergone acid hydrolysis and centrifugation at 12,000 xg and 4° C. for 30 minutes, and dividing the resulting value by the initial weight of agarose added.
- hydrolysis was performed with 0.5% (w/v), 1% (w/v), or 2% (w/v) phosphoric acid at a reaction temperature of 110° C., 120° C., 130° C., or 140° C. for 5 minutes or 10 minutes.
- a derivatization process for GC/TOF-MS analysis is as follows.
- the pretreatment reaction product was centrifuged at 16,000 xg for 5 minutes, and then 20 ⁇ l of the supernatant was dried with a speed bag.
- 10 ⁇ l of 4% (w/v) O-methylhydroxylamine hydrochloride in pyridine was added to the sample dried for derivatization and a reaction was allowed to occur therebetween at 30° C. for 90 minutes and then 45 ⁇ l of N-methyl-N-(trimethylsilyl)trifluoroacetamide was added thereto and a reaction was allowed to occur therebetween at 37° C. for 30 minutes.
- Device conditions for the analysis are as follows.
- a column used for the analysis was RTX-5Sil MS (30 m ⁇ 0.25 mm i.d., 25 ⁇ m film thickness, Resteck), the column temperature was first maintained at 50° C. for 1 minute and raised to 330° C. at a heating rate of 20° C./min, and then the temperature was maintained at 330° C. for 5 minutes. 1 ⁇ l of each sample was analyzed at a split ratio of 5.
- a gene encoding ⁇ -agarooligosaccharide hydrolase was obtained through PCR using Saccharophagus degradans 2-40 T (ATCC 43961) as a template and the following primers:
- Forward primer (SEQ ID NO: 3) 5′-ATACATATGAATAGACTTACACTACCGCCTTCTTCTCGT-3′; Reverse primer: (SEQ ID NO: 4) 5′-ATAGCGGCCGCGCTCCTACTCGAGACAAACTCAGCAAATGC-3′
- 100 ⁇ l of the PCR reaction mixture was prepared by adding 250 ⁇ M dNTP, 20 pmol of each primer, 1.5 mM MgCl 2 , 10 ⁇ l of a 10x buffer, 100 ng of a DNA template, and 1 unit of pfu polymerase, and PCR was performed as follows: initial denaturation at 95° C. for 5 minutes, then 25 cycles of denaturation at 95° C. for 1 minute, annealing at 55° C. for 30 seconds, and extension at 72° C. for 3 minutes.
- DNA fragments obtained by PCR were digested with NdeI/NotI restriction enzymes, purified on 1% agarose gel, and ligated into a pET21a plasmid digested with the same restriction enzymes to construct pET21a-Sde_BAga for each case.
- the constructed plasmids were introduced into Escherichia coli BL21 (DE3).
- Escherichia coli BL21 DE3
- the cells were cultured in 10 mL of LB broth containing 100 ⁇ g/mL of ampicillin in a 50 mL-conical tube at 37° C. for 9 hours.
- the lysate was centrifuged at 16,000 xg for 10 minutes at 4° C. to collect a supernatant.
- a recombinant enzyme included in the collected supernatant was purified using a HisTrap column (5 mL, GE Health Care), and then the size of each purified protein was confirmed using an SDS-PAGE gel (see FIG. 4 a ).
- the salt (imidazole) used in protein purification was removed using a desalting column.
- the concentration of the recombinant protein enzyme from which the salt was removed was quantified using a BCA assay.
- Agarooligosaccharide hydrolase reaction conditions are as follows. The acid hydrolysate obtained under the above conditions was neutralized to a pH of 5 to 6 using 5 M NaOH, and then a reaction was allowed to occur at 37° C. and 200 rpm for 12 hours.
- the reaction product obtained after the enzymatic reaction was analyzed through thin layer chromatography (TLC) (see FIG. 4 b ) and GC/TOF-MS and HPLC (see FIG. 4 c ), and TLC, GC/TOF-MS, and HPLC analyses conditions were the same as those used in Example 1.
- the reaction products obtained in Example 3 were AHG and D-galactose, and yeast culture was performed in order to remove D-galactose.
- yeast strain Saccharomyces cerevisiae D452-2 was used, and the strain was pre-cultured in YPD broth at 30° C. and 200 rpm for 24 hours. After culturing, the culture broth was centrifuged at 6,000 xg for 10 minutes to obtain a cell pellet, the cell pellet was washed with a Tris-HCl buffer (pH 7.4), and then centrifuged once again under the same conditions to obtain a cell pellet.
- Tris-HCl buffer pH 7.4
- the present invention can be used for the production of a high yield of 3,6-anhydro-L-galactose.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to a method for producing anhydrous galactose derived from seaweed, and provides an improved production yield of 3,6-anhydro-L-galactose (AHG) from agarose or agar through multiple steps involving acid hydrolysis of agar or agarose for producing agarobiose, neutralization of the acid hydrolysate, and purification of AHG using a microorganism metabolizing galactose after enzymatic hydrolysis of agarobiose.
Description
- This application is a Divisional application of U.S. application Ser. No. 16/467,129 filed Jun. 6, 2019, which is a National Stage of International Application No. PCT/KR2017/013493, filed on Nov. 24, 2017, which claims priority from Korean Patent Application No. 10-2016-0165598, filed on Dec. 7, 2016, the disclosures of which are incorporated herein by reference.
- The present invention relates to a method of producing anhydrous galactose derived from seaweed, in which the production yield of 3,6-anhydro-L-galactose is enhanced using a microorganism in a purification process after acid treatment, neutralization, and enzymatic hydrolysis of agarose or agar.
- A major polysaccharide constituting red algae is agarose, and agarose is a polymer in which 3,6-anhydro-L-galactose (hereinafter, referred to as “AHG”) and D-galactose are alternately bound via α-1,3 linkage and β-1,4 linkage. Among these, AHG is a multifunctional high-value-added material having an anticariogenic function and a colorectal cancer prevention function as well as cosmetic whitening and moisturizing functions. Therefore, it is very important to efficiently produce AHG from agar or agarose, which is the main carbohydrate of red algae, and efficiently purify AHG.
- Methods of producing AHG are as follows. First, there is a method of producing AHG by hydrolyzing agarose or agar using a strong acid at a high temperature. This method is inexpensive and simple, but disadvantageous in that AHG and D-galactose, which are monosaccharides, are decomposed into 5-hydroxymethyl furfural (5-HMF) at high temperatures, resulting in a reduced AHG production yield. Second, there is a method of producing AHG by hydrolyzing agarose or agar using an enzyme at room temperature. However, this method is not capable of allowing a high concentration reaction due to low solubility of agarose or agar, and thus the concentration of produced AHG is very low and accordingly, separation and purification costs increase, resulting in a reduced AHG production yield. Third, agarose or agar is decomposed into agarooligosaccharides (AOSs) using a weak acid such as acetic acid, and then the AOSs are produced as neoagarobiose (NAB) through an enzymatic reaction of exo-type β-agarase II. However, in this case, agarotriose is produced as a by-product, and it is necessary to introduce an additional enzyme called agarolytic β-galactosidase (ABG) in order to decompose the agarotriose. Subsequently, AHG and D-galactose, which are monosaccharides, may be obtained through an enzymatic reaction of neoagarobiose hydrolase (NABH). However, when acetic acid is used in a pretreatment reaction, which is the first step of this process, a large amount of salt is produced in the subsequent neutralization process. In addition, since a recombinant enzyme must be produced through fermentation separately in order to produce an enzyme for the reaction, the process is very complicated and production costs increase, resulting in reduced economic efficiency. Fourth, there is a pretreatment method using a low concentration of a neutral buffer at a high temperature (170° C.), but this method requires a high-temperature and high-pressure reactor in mass production. In addition, AHG is over-decomposed into 5-HMF during the pretreatment process, thus reducing AHG production yield.
- An object of the present invention is to provide a method of producing agarobiose from agarose or agar through strong acid treatment and neutralization.
- Another object of the present invention is to provide a method of producing 3,6-anhydro-L-galactose through anaerobic and aerobic culturing of a microorganism with agarose or agar having undergone strong acid treatment, neutralization, and enzymatic hydrolysis.
- To achieve the aforementioned objects, the present invention provides a method of producing agarobiose, including allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, in which a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w).
- The present invention also provides a method of producing 3,6-anhydro-L-galactose, including: a step of allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w);
- a step of allowing the reaction product to react with agarooligosaccharide hydrolase, which uses agarobiose as a substrate; and
- a step of culturing a microorganism having the ability to metabolize galactose in the presence of the hydrolysate obtained by the above step and obtaining 3,6-anhydro-L-galactose from the resulting microorganism culture broth.
- According to the present invention, AHG is obtained without a separate existing purification process through established optimum conditions capable of producing a high concentration of agarobiose by treatment of agarose or agar with a strong acid and neutralization thereof, and through culturing of an enzyme using agarobiose as a substrate and a microorganism using galactose as a substrate, and thus AHG loss can be reduced, thus providing an effect of obtaining AHG with a high yield.
-
FIG. 1 is a schematic diagram illustrating production of AHG from agarose or agar and purification thereof, wherein A diagram inserted within theFIG. 1 illustrates a process of producing AHG through conventional enzyme saccharification and purifying AHG using a microorganism, and B diagram inserted within theFIG. 1 illustrates an AHG production process of the present invention. - A of
FIG. 2 is a graph showing the degree of liquefaction obtained after agarose was treated with a 0.5% (w/v) strong acid, followed by acid hydrolysis at 140° C. for 10 minutes according to the AHG production process of the present invention, and B ofFIG. 2 illustrates TLC analysis results of the reaction product. -
FIG. 3a illustrates TLC analysis results of a reaction product obtained by treating agarose with 0.5% (w/v), 1% (w/v), or 2% (w/v) phosphoric acid, followed by acid hydrolysis at 110° C. for 10 minutes according to the AHG production process of the present invention. -
FIG. 3b illustrates GC-TOF/MS analysis results of a reaction product obtained by treating agarose with 2% (w/v) phosphoric acid, followed by acid hydrolysis at 110° C. for 10 minutes according to the AHG production process of the present invention. -
FIG. 4a illustrates SDS-PAGE analysis results of recombinant agarooligosaccharide hydrolase. -
FIG. 4b is a TLC image showing a reaction product obtained by reacting agar or agarose having undergone acid treatment and neutralization with the agarooligosaccharide hydrolase. -
FIG. 4c illustrates GC-TOF/MS analysis results of a reaction product obtained by reacting agar or agarose having undergone acid treatment and neutralization with the agarooligosaccharide hydrolase. -
FIG. 5 is a set of TLC images showing results of confirming AHG purification using yeast, which is a GRAS microorganism, from agarose or agar, according to the AHG production process of the present invention, at different yeast culture time points. -
FIG. 6 illustrates the saccharification yield at different time points after acid hydrolysis of 20% (w/v) agar with phosphoric acid at a concentration of 1% (w/v), 2% (w/v), or 3% (w/v) at 90° C. according to the AHG production process of the present invention. -
FIG. 7a illustrates HPLC analysis results of a reaction product obtained after treatment of agar with 1% (w/v) phosphoric acid and acid hydrolysis of the treated-agar at 90° C. for 480 minutes according to the AHG production process of the present invention. -
FIG. 7b illustrates HPLC analysis results of a reaction product obtained after treatment of agar with 2% (w/v) phosphoric acid and acid hydrolysis of the treated-agar at 90° C. for 480 minutes according to the AHG production process of the present invention. -
FIG. 7c illustrates HPLC analysis results of a reaction product obtained after treatment of agar with 3% (w/v) phosphoric acid and acid hydrolysis of the treated-agar at 90° C. for 480 minutes according to the AHG production process of the present invention. - Hereinafter, the configuration of the present invention will be described in detail.
- The present invention relates to a method of producing agarobiose, including: allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with a strong acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, in which a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w).
- The present invention also provides a method of producing 3,6-anhydro-L-galactose, including: a step of allowing agarose or agar used as a substrate in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight to react with phosphoric acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and performing neutralization to obtain a reaction product including agarobiose, wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w);
- a step of allowing the reaction product to react with agarooligosaccharide hydrolase, which uses agarobiose as a substrate; and
- a step of culturing a microorganism having the ability to metabolize galactose in the presence of the hydrolysate obtained by the above step and obtaining 3,6-anhydro-L-galactose from the resulting microorganism culture broth.
- To address problems found in conventionally known AHG production methods, first, the inventors of the present invention established a condition of minimum production of 5-HMF even when a strong acid was used for the production of AHG and performed a pretreatment reaction on agarose or agar at a high concentration, thereby obtaining agarooligosaccharides, particularly agarobiose with a high yield at a high concentration (see
FIG. 1 ). Second, the agarobiose and agarooligosaccharides obtained with a high yield at a high concentration is neutralized with a strong base, and at this time, salt produced through neutralization (e.g., phosphate) is not removed and used as a buffer solution in the next step, i.e., the agarooligosaccharide hydrolase reaction. Third, AHG and D-galactose are produced at high concentrations using agarooligosaccharide hydrolase, which efficiently degrades agarobiose. Fourth, AHG is purified using yeast, which is generally recognized as a safe (GRAS) microorganism for humans. Under anaerobic or aerobic conditions, AHG and D-galactose, which are enzyme reaction products, are supplied as carbon sources during yeast culture, and among these, only galactose may be selectively metabolized to thereby purify AHG (see B ofFIG. 1 ). This purification method does not use an organic solvent harmful to the human body, and since the amount of AHG lost during the purification process is almost none, the purified AHG may be obtained with a high yield. - The concentration of the strong acid used in the strong acid treatment of agarose or agar may range from 0.1% (w/v) to 5% (w/v), more particularly 0.5% (w/v) to 3% (w/v). When the concentration of the strong acid is within the above range, the production of 5-HMF by strong acid treatment of agarose or agar may be minimized, and at the same time, a high concentration of agarobiose may be produced, and thus the production of AHG with a high yield is possible.
- The treatment of agarose or agar with a strong acid may be a reaction of agarose or agar with a 0.1% (w/v) to 5% (w/v) strong acid at 80° C. to 140° C. for 5 minutes to 500 minutes. More particularly, the treatment may be a reaction of agarose as a substrate with a 0.5% (w/v) to 2% (w/v) strong acid at 100° C. to 140° C. for 5 minutes to 20 minutes. More particularly, the treatment may be a reaction of agar as a substrate with a 1% (w/v) to 3% (w/v) strong acid at 80° C. to 100° C. for 60 minutes to 480 minutes.
- The strong acid may be phosphoric acid, sulfuric acid, hydrochloric acid, nitric acid, or the like. More specifically, the strong acid may be phosphoric acid.
- After the treatment of agarose or agar with a strong acid, agarooligosaccharides including a high concentration of agarobiose may be produced.
- The amount of the agarose or agar used in the strong acid treatment may range from 10% (w/v) to 37% (w/v), more particularly 15% (w/v) to 31% (w/v), and more particularly 16.8% to 30.7% (w/w), with respect to a dry weight. When the amount of the agarose or agar is within the above range, a degree of liquefaction of 90%, 95%, or 98% may be obtained. When the amount of the agarose or agar is outside the above range, a substrate degradation rate may be significantly reduced.
- The strong acid-treated agarose or agar is neutralized to a pH of 5 to 7 by adding a strong base thereto.
- As the strong base, NaOH, KOH, Ca(OH)2, Ba(OH)2, or the like may be used, but the present invention is not limited thereto.
- The agarooligosaccharide hydrolase is an enzyme that decomposes agarobiose as a substrate into D-galactose and 3,6-anhydro-L-galactose, and may include the amino acid sequences set forth in SEQ ID NO: 1.
- The agarooligosaccharide hydrolase may be transcribed and translated through a DNA segment, i.e., a coding gene, involved in producing a polypeptide including an intervening sequence between individual coding segments as well as a region before and after the coding region of the enzyme. For example, the agarooligosaccharide hydrolase may be transcribed and translated from the sequences set forth in SEQ ID NO: 2, but is not particularly limited thereto. Also, as mutant proteins having one or more substitutions, deletions, dislocations, additions, or the like of the enzyme, proteins having an agarobiose hydrolytic activity are also within the scope of the enzyme of the present invention. Preferably, the agarooligosaccharide hydrolase includes an amino acid sequence with at least 80% homology, at least 85% homology, at least 90% homology, at least 93% homology, at least 94% homology, at least 95% homology, at least 96% homology, at least 97% homology, at least 98% homology, and at least 99% homology to the amino acid sequences set forth in SEQ ID NO: 1.
- The agarooligosaccharide hydrolase may be derived from Saccharophagus degradans 2-40T, but the present invention is not particularly limited thereto.
- The agarooligosaccharide hydrolase may be separated and purified from a supernatant of a culture of Saccharophagus degradans 2-40T, and may be produced and separated: from strains other than Saccharophagus degradans using a genetic recombination technique; or by an artificial chemical synthesis method or the like. When the recombination technique is used, a culture supernatant or a supernatant of Saccharophagus degradans may be used instead of the agarooligosaccharide hydrolase, but the present invention is not particularly limited thereto. According to one embodiment, the agarooligosaccharide hydrolase may be obtained from E. coli transformed with a recombinant vector including the base sequences set forth in SEQ ID NO: 2 or a culture broth thereof.
- A reaction between the agarobiose and the agarooligosaccharide hydrolase may be performed at a temperature of 20° C. to 40° C. and 100 rpm to 300 rpm for 5 hours to 48 hours. More particularly, the reaction therebetween may be performed at a temperature of 30° C. to 40° C. for 10 hours to 24 hours.
- In the present specification, the terms “protein” and “polypeptide” may be used interchangeably.
- In the present invention, a polypeptide having a sequence homology of a certain percentage (for example, 80%, 85%, 90%, 95%, or 99%) with respect to another sequence means that two sequences has the same amino acid residues at the above percentage upon sequence comparison when the two sequences are aligned. The alignment and percentage homology or identity may be determined using any suitable software program known in the related art, for example, those described in Current Protocols in Molecular Biology (F. M. Ausubel, et al., (eds) 1987
Supplement 30 section 7.7.18). A preferred program includes the GCG Pileup program, FASTA (Pearson, et al., 1988 Proc. Natl. Acad. Sci. USA 85: 2444-2448), and BLAST (BLAST Manual, Altschul et al., Natl. Cent. Biotechnol. Inf., Natl Lib. Med. (NCIB NLM NIH), Bethesda, Md., and Altschul et al., 1997 NAR 25: 3389-3402). Another preferred alignment program is ALIGN Plus (Scientific and Educational Software, PA), which preferably uses basic parameters. Still another preferred sequence software program which may be used herein is a TFASTA Data Searching program available in Sequence Software Package Version 6.0 (Genetics Computer Group, University of Wisconsin, Madison Wis.). - In the present invention, the term “recombination” used in connection with cells, nucleic acids, proteins, or vectors indicates that the cells, nucleic acids, proteins, or vectors are modified by introduction of heterologous nucleic acids or proteins or alteration of inherent nucleic acids or proteins, or that the cells are derived from such modified cells. That is, the recombinant cells, for example, express genes which are not found in the cells in an inherent (non-recombinant) form, or express inherent genes which are expressed abnormally upon expression or not expressed at all.
- In this specification, the term “nucleic acid” encompasses all types of single- or double-stranded DNAs, RNAs, and chemical variants thereof. The terms “nucleic acid” and “polynucleotide” may be used interchangeably herein. Since the genetic codes are degenerate, one or more codons may be used to encode a specific amino acid, and the present invention encompasses polynucleotides encoding certain amino acid sequences.
- The term “introduction” used to describe an insertion of a nucleic acid sequence into cells refers to “transfection,” “transformation,” or “transduction,” and encompasses references to the integration of a nucleic acid sequence into eukaryotic or prokaryotic cells. In this case, the nucleic acid sequence is integrated into the genome (for example, a chromosome, a plasmid, a plastid, or mitochondrial DNA) of a cell, and converted into an autonomous replicon or expressed temporarily.
- In the method of producing AHG of the present invention, agarobiose is hydrolyzed into D-galactose and AHG by the agarooligosaccharide hydrolase, which uses agarobiose as a substrate, and when a microorganism having the ability to metabolize galactose is cultured therewith under anaerobic or aerobic conditions, galactose is consumed in the microorganism culture broth, and only AHG remains. Therefore, there is no need to go through an additional process of separately purifying AHG from a hydrolysate including galactose and AHG.
- The microorganism having the ability to metabolize galactose may be any one of: lactic acid bacteria including Bifidobacterium and Lactobacillus such as L. casei, L. acidophilus, L. bulgaricus, B. longum, B. bifidum, Actiregularis, and the like; Bacillus; Streptomyces; Corynebacterium; Zymomonas such as Z. mobilis and the like; Escherichia coli; and yeasts such as Saccharomyces cerevisiae, Pichia pastoris, and the like. These are the aforementioned harmless GRAS microorganisms which metabolize galactose, and thus only a microorganism and AHG remain in a microorganism culture broth.
- Therefore, a microorganism or cell debris is removed by centrifugation or filtration of the microorganism culture broth without the conventional purification process, and AHG remains in the remaining liquid, so that AHG can be obtained with a high yield.
- The microorganism having the ability to metabolize galactose may be cultured under aerobic or anaerobic conditions. More preferably, the microorganism may be cultured under anaerobic conditions, and anaerobic culturing conditions such as culture medium, culture temperature, time, and the like can be performed within the range of understanding of those skilled in the art, and the present invention is not particularly limited thereto.
- Hereinafter, the present invention will be described in more detail with reference to examples according to the present invention, but these examples are not intended to limit the scope of the present invention.
- When agarose or agar is hydrolyzed with a strong acid, AHG or D-galactose is over-decomposed and converted to 5-HMF. Therefore, acid hydrolysis was performed in a microwave digestion system using dilute phosphoric acid obtained by diluting phosphoric acid.
- To examine the hydrolytic effect of dilute phosphoric acid, first, the amount of substrate added was optimized. 16.8% (w/v), 23.8% (w/v), 30.7% (w/v), or 36.8% (w/v) of an agarose substrate was subjected to acid hydrolysis using 0.5% (w/v) phosphoric acid at 140° C. for 10 minutes. At this time, the amount of used agarose is based on a dry weight. The degree of liquefaction was expressed as a percentage of a value obtained by subtracting, from an initial weight (g) of agarose added, the amount (g) of precipitate dried at 105° C. for 12 hours after having undergone acid hydrolysis and centrifugation at 12,000 xg and 4° C. for 30 minutes, and dividing the resulting value by the initial weight of agarose added.
- As a result, as shown in A of
FIG. 2 , when the substrate was added in an amount of 16.8% to 30.7%, a degree of liquefaction of 98% or higher was obtained, whereas the degree of liquefaction under a condition of adding 36.8% of the substrate was significantly reduced, i.e., 5%. From this result, it was confirmed that, as illustrated in B ofFIG. 2 , which illustrates TLC measurement results, agarose was not adequately degraded under a condition of adding 36.8% of the substrate. In the production process, it is very important to add a high concentration of substrate since AHG, which is a final product, can be produced at a concentration as high as possible. In addition, the consumption of water and energy and the size of a reactor may be reduced, and thus production costs may be lowered. Thus, a subsequent acid hydrolysis condition was established by selecting 30.7%, which is the largest amount of substrate added. - To produce agarooligosaccharides, especially agarobiose, which is effective for use in acid hydrolysis, hydrolysis was performed with 0.5% (w/v), 1% (w/v), or 2% (w/v) phosphoric acid at a reaction temperature of 110° C., 120° C., 130° C., or 140° C. for 5 minutes or 10 minutes.
- Table 1 shows results of confirming the degree of liquefaction and the production yields of agarobiose and 5-HMF in accordance with hydrolysis conditions.
-
TABLE 1 Degree of Agarobiose 5-HMF liquefac- production production tion yield yield Acid pretreatment condition (%, w/w) (%, w/w) (%, w/w) Phosphoric 120° C., 10 min 18.5 ± 6.3 4.0 ± 0.1 0.0 ± 0.0 acid 0.5% 130° C., 5 min 91.1 ± 7.0 19.5 ± 5.2 0.2 ± 0.1 (w/v) 130° C., 10 min 99.3 ± 0.1 44.7 ± 0.9 0.9 ± 0.0 140° C., 5 min 99.0 ± 1.3 21.8 ± 5.1 0.2 ± 0.1 140° C., 10 min 99.2 ± 0.1 57.2 ± 0.2 4.2 ± 0.3 Phosphoric 110° C., 5 min 64.4 ± 9.7 10.5 ± 1.7 0.0 ± 0.0 acid 1% 110° C., 10 min 99.4 ± 0.2 39.0 ± 1.4 0.2 ± 0.0 (w/v) 120° C., 5 min 93.8 ± 0.7 24.3 ± 5.1 0.1 ± 0.0 120° C., 10 min 99.7 ± 0.2 59.1 ± 3.7 0.5 ± 0.1 130° C., 5 min 99.9 ± 0.4 66.1 ± 1.1 1.2 ± 0.3 130° C., 10 min 99.2 ± 0.1 49.3 ± 10.4 7.3 ± 3.3 140° C., 5 min 99.4 ± 0.1 62.5 ± 1.1 2.9 ± 0.6 140° C., 10 min 98.4 ± 0.2 32.4 ± 0.8 11.1 ± 2.2 Phosphoric 110° C., 5 min 99.6 ± 0.2 47.2 ± 7.1 0.2 ± 0.1 acid 2% 110° C., 10 min 99.4 ± 0.3 70.0 ± 1.2 1.3 ± 0.6 (w/v) 120° C., 5 min 99.3 ± 0.1 67.0 ± 2.6 0.8 ± 0.4 120° C., 10 min 99.3 ± 0.1 64.4 ± 3.9 2.5 ± 1.3 130° C., 5 min 99.3 ± 0.2 65.4 ± 2.1 2.1 ± 0.5 130° C., 10 min 99.2 ± 0.2 44.6 ± 6.8 9.0 ± 2.3 140° C., 5 min 99.5 ± 0.1 53.1 ± 6.9 5.7 ± 1.4 140° C., 10 min 98.9 ± 0.1 25.2 ± 3.0 16.9 ± 1.9 - As shown in Table 1, a degree of liquefaction of 18.5% to 93.8% was exhibited under conditions of 0.5% phosphoric acid, 120° C., 10 min, and 130° C., 5 min and under conditions of 1% phosphoric acid, 110° C., 5 min, and 120° C., 5 min, from which it was confirmed that agarose was unable to be completely hydrolyzed. However, as acid concentration and temperature increased, the monosaccharide was over-decomposed, and thus 5-HMF yield was also increased. In contrast, as acid concentration, temperature, and reaction time increased, the degree of liquefaction increased and agarobiose yield also increased.
- To analyze the types of reaction products in accordance with the above conditions, TLC, GC/TOF-MS, and HPLC analyses were performed.
- For TLC, 1 μl of an enzyme reaction product was loaded onto a silica gel plate and developed on a mobile phase consisting of a mixture of n-butanol, ethanol, and water in a volume ratio (v/v/v) of 3:1:1 for 2 hours, followed by color development using 10% sulfuric acid and 0.2% 1,3-dihydroxynaphthalene.
- A derivatization process for GC/TOF-MS analysis is as follows. The pretreatment reaction product was centrifuged at 16,000 xg for 5 minutes, and then 20 μl of the supernatant was dried with a speed bag. 10 μl of 4% (w/v) O-methylhydroxylamine hydrochloride in pyridine was added to the sample dried for derivatization and a reaction was allowed to occur therebetween at 30° C. for 90 minutes and then 45 μl of N-methyl-N-(trimethylsilyl)trifluoroacetamide was added thereto and a reaction was allowed to occur therebetween at 37° C. for 30 minutes. Device conditions for the analysis are as follows. A column used for the analysis was RTX-5Sil MS (30 m×0.25 mm i.d., 25 μm film thickness, Resteck), the column temperature was first maintained at 50° C. for 1 minute and raised to 330° C. at a heating rate of 20° C./min, and then the temperature was maintained at 330° C. for 5 minutes. 1 μl of each sample was analyzed at a split ratio of 5.
- For the HPLC analysis, each sample was analyzed using a KS-802 column (Shodex) at a column temperature of 80° C. and a flow rate of 0.5 mL/min. At this time, water was used as a mobile phase.
- As shown in
FIG. 3a and Table 1, it was confirmed that, while a higher degree of polymerization (DP) was exhibited under a condition of a lower concentration of phosphoric acid, agarobiose having a DP of 2 was mainly produced as acid concentration increased. Among the above conditions, under conditions of 1% phosphoric acid and 130° C., 5 min and conditions of 2% phosphoric acid, 110° C., 10 min, and 120° C., 5 min, the agarobiose yield was highest, i.e., 66.1%, 67.0%, and 70.0% for the respective conditions (seeFIG. 3b ), and under these conditions, the 5-HMF yield was low, i.e., 1.2%. - A gene encoding β-agarooligosaccharide hydrolase was obtained through PCR using Saccharophagus degradans 2-40T (ATCC 43961) as a template and the following primers:
-
Forward primer: (SEQ ID NO: 3) 5′-ATACATATGAATAGACTTACACTACCGCCTTCTTCTCGT-3′; Reverse primer: (SEQ ID NO: 4) 5′-ATAGCGGCCGCGCTCCTACTCGAGACAAACTCAGCAAATGC-3′ - 100 μl of the PCR reaction mixture was prepared by adding 250 μM dNTP, 20 pmol of each primer, 1.5 mM MgCl2, 10 μl of a 10x buffer, 100 ng of a DNA template, and 1 unit of pfu polymerase, and PCR was performed as follows: initial denaturation at 95° C. for 5 minutes, then 25 cycles of denaturation at 95° C. for 1 minute, annealing at 55° C. for 30 seconds, and extension at 72° C. for 3 minutes. DNA fragments obtained by PCR were digested with NdeI/NotI restriction enzymes, purified on 1% agarose gel, and ligated into a pET21a plasmid digested with the same restriction enzymes to construct pET21a-Sde_BAga for each case.
- The constructed plasmids were introduced into Escherichia coli BL21 (DE3). To pre-culture the recombinant E. coli having the agarooligosaccharide hydrolase gene introduced therein, the cells were cultured in 10 mL of LB broth containing 100 μg/mL of ampicillin in a 50 mL-conical tube at 37° C. for 9 hours. Thereafter, 2 mL of the pre-cultured solution was inoculated into 100 mL of the present culture broth of the same medium composition, and then when the optical density value reached the mid-exponential phase (OD 0.4-0.6) using an optical density spectroscope, 0.1 mM isopropyl-beta-di-thiogalactopyranoside (IPTG) was added to allow induction at 30° C. for 16 hours. Then, the cell broth was centrifuged at 16,000 xg for 20 minutes at 4° C., and then cells were recovered. The recovered cells were dispersed in 30 mL of a 20 mM Tris-HCl buffer (pH 7.4), and then the cells were lysed using a sonicator. Subsequently, the lysate was centrifuged at 16,000 xg for 10 minutes at 4° C. to collect a supernatant. A recombinant enzyme included in the collected supernatant was purified using a HisTrap column (5 mL, GE Health Care), and then the size of each purified protein was confirmed using an SDS-PAGE gel (see
FIG. 4a ). The salt (imidazole) used in protein purification was removed using a desalting column. The concentration of the recombinant protein enzyme from which the salt was removed was quantified using a BCA assay. - 30.7 wt % (w/v) of agarose and agar was allowed to react under the conditions established in Example 1, i.e., 2% phosphoric acid and 110° C., 10 min (see Table 2). The amounts of both agarose and agar were based on a dry weight.
- Agarooligosaccharide hydrolase reaction conditions are as follows. The acid hydrolysate obtained under the above conditions was neutralized to a pH of 5 to 6 using 5 M NaOH, and then a reaction was allowed to occur at 37° C. and 200 rpm for 12 hours.
- The reaction product obtained after the enzymatic reaction was analyzed through thin layer chromatography (TLC) (see
FIG. 4b ) and GC/TOF-MS and HPLC (seeFIG. 4c ), and TLC, GC/TOF-MS, and HPLC analyses conditions were the same as those used in Example 1. - As illustrated in
FIGS. 4b and 4c , it was confirmed that agarobiose was converted into AHG and D-galactose by agarooligosaccharide hydrolase. At this time, the AHG yield obtained with respect to the amount (g) of agarose added was 43.3%. - The reaction products obtained in Example 3 were AHG and D-galactose, and yeast culture was performed in order to remove D-galactose. As a yeast strain, Saccharomyces cerevisiae D452-2 was used, and the strain was pre-cultured in YPD broth at 30° C. and 200 rpm for 24 hours. After culturing, the culture broth was centrifuged at 6,000 xg for 10 minutes to obtain a cell pellet, the cell pellet was washed with a Tris-HCl buffer (pH 7.4), and then centrifuged once again under the same conditions to obtain a cell pellet.
- For culturing, the cell pellet of S. cerevisiae D452-2 was inoculated into a minimal medium containing 3.35 g/L of a yeast nitrogen base and 0.4 g/L of CSM, using enzymatic reaction products, i.e., AHG and D-galactose, as carbon sources. The cell pellet was cultured at 30° C. and 200 rpm for 42 hours, and then TLC and GC-TOF/MS were performed, from which it was confirmed that D-galactose was completely consumed and only AHG remained (see
FIG. 5 ), and the AHG yield was calculated as 33.2% (see Table 2). -
TABLE 2 Yield (g product/100 g Amount (g) input substrate) Processing condition Agarose Agar Agarose Agar Step Initial 147.2 134.4 NA* NA substrate Acid hydrolysis Agarobiose 132.6 83.8 90.1 62.4 (DP2) Treatment with AHG/ 63.4/70.5 29.2/32.9 43.3/47.9 21.8/24.5 agarooligosaccharide galactose hydrolase Yeast fermentation AHG 48.8 22.5 33.2 16.7 *not applicable - Monosaccharide yield and maximum substrate concentration in saccarification according to the present invention and conventional saccarification processes were compared. The results thereof are shown in Table 3 below.
-
TABLE 3 Acetic acid Tris-HCl buffer pretreatment pretreatment and enzymatic and enzymatic saccarification saccarification Enzymatic using Aga50D, using Aga50D, saccarification ABG, and NABH ABG, and NABH using Agarose CH Lee et al. CH Lee et al. Agal6B, saccarification Process Biochem Process Biochem Aga50D, and Present method (2015) (2015) NABH invention Monosaccharide 50.5 44.9 72.5 62.6 yield (% of theoretical maximum) Maximum 15% 5% 1% 30.7% substrate concentration (w/v) - As shown in Table 3, the maximum substrate concentration was significantly higher in the case of the present invention than in the existing processes.
- Hydrolysis was performed using 1% (w/v), 2% (w/v), or 3% (w/v) phosphoric acid at a reaction temperature of 90° C. for 480 minutes (8 hours), in the same manner as in Example 1, except that 20% (w/w) of agar was used as a substrate.
- As illustrated in
FIG. 6 , the saccarification yield under each condition was increased over time. - To analyze the types of reaction products in accordance with the above conditions, HPLC analysis was performed in the same manner as in Example 1.
- As illustrated in
FIGS. 7a, 7b and 7c , the concentration of agarobiose was 143.3 g/L under a condition of 1% phosphoric acid and 480 min, the concentration of agarobiose was 162.5 g/L under a condition of 2% phosphoric acid and 270 min, and the concentration of agarobiose was 172.7 g/L under a condition of 3% phosphoric acid and 150 min. These are yields corresponding to 64%, 73%, and 77%, respectively, with respect to the amount of added agar. The amount of 5-HMF as a by-product was very small, i.e., 4.4 g/L and 3.7 g/L under conditions of 2% phosphoric acid and 3% phosphoric acid, respectively. The method of the present invention is advantageous in that there is no need for an expensive high-pressure reactor since acid hydrolysis is performed at a relatively low temperature, and there is more safety at work. - The present invention can be used for the production of a high yield of 3,6-anhydro-L-galactose.
Claims (2)
1. A method of producing agarobiose comprising
reacting agarose or agar in an amount of 10% (w/v) to 37% (w/v) with respect to a dry weight with a phosphoric acid at a concentration of 0.1% (w/v) to 5% (w/v) at 80° C. to 140° C. for 5 minutes to 500 minutes and then adding a strong base therein such that a pH of a reaction product comprising agarobiose is adjusted to 5 to 7,
wherein a yield of 5-hydroxymethyl furfural in the reaction product is less than 1.5% (w/w), and
wherein the reaction product does not include agarotriose.
2. The method of claim 1 , wherein the strong base comprises one or more selected from the group consisting of NaOH, KOH, Ca(OH)2, and Ba(OH)2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/586,649 US20220220522A1 (en) | 2016-12-07 | 2022-01-27 | Method for producing anhydrous galactose derived from seaweed |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0165598 | 2016-12-07 | ||
KR1020160165598A KR101864800B1 (en) | 2016-12-07 | 2016-12-07 | Method for preparing anhydrogalactose derived from marine macroalgae |
PCT/KR2017/013493 WO2018105932A1 (en) | 2016-12-07 | 2017-11-24 | Method for producing anhydrous galactose derived from seaweed |
US201916467129A | 2019-06-06 | 2019-06-06 | |
US17/586,649 US20220220522A1 (en) | 2016-12-07 | 2022-01-27 | Method for producing anhydrous galactose derived from seaweed |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,129 Division US11268114B2 (en) | 2016-12-07 | 2017-11-24 | Method for producing anhydrous galactose derived from seaweed |
PCT/KR2017/013493 Division WO2018105932A1 (en) | 2016-12-07 | 2017-11-24 | Method for producing anhydrous galactose derived from seaweed |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220220522A1 true US20220220522A1 (en) | 2022-07-14 |
Family
ID=62491553
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,129 Active US11268114B2 (en) | 2016-12-07 | 2017-11-24 | Method for producing anhydrous galactose derived from seaweed |
US17/586,649 Abandoned US20220220522A1 (en) | 2016-12-07 | 2022-01-27 | Method for producing anhydrous galactose derived from seaweed |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,129 Active US11268114B2 (en) | 2016-12-07 | 2017-11-24 | Method for producing anhydrous galactose derived from seaweed |
Country Status (4)
Country | Link |
---|---|
US (2) | US11268114B2 (en) |
KR (1) | KR101864800B1 (en) |
CN (1) | CN110291203B (en) |
WO (1) | WO2018105932A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102124590B1 (en) * | 2018-09-06 | 2020-06-19 | 고려대학교 산학협력단 | A method for producing the novel sugar alcohols from red macroalgae |
KR102583684B1 (en) | 2021-05-10 | 2023-10-05 | 고려대학교 산학협력단 | Novel alkyl-agarobioside from agar, method for producing the same, or use thereof |
KR102642881B1 (en) | 2021-06-18 | 2024-03-04 | 고려대학교 산학협력단 | Recombinant yeast Saccharomyces boulardii for producing neoagarooligosaccharides and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105029A1 (en) * | 1997-11-11 | 2003-06-05 | Takara Shuzo Co., Ltd. | Drugs, foods or drinks with the use of algae-derived physiologically active substances |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102405282B (en) * | 2009-03-27 | 2014-02-12 | 高丽大学校产学协力团 | Novel alpha-neoagarobiose hydrolase, and method for obtaining monosaccharide using same |
KR101087265B1 (en) * | 2009-12-23 | 2011-11-29 | 고려대학교 산학협력단 | Enzymatic production of 3,6-anhydro-L-galactose and galactose from agar using crude enzymes of Saccharophagus degradans 2-40 and the quantitative analytical method for 3,6-anhydro-L-galactose |
CN111544437A (en) | 2012-01-18 | 2020-08-18 | 高丽大学校产学协力团 | Preparation method and application of 3, 6-anhydro-L-galactose |
KR101521711B1 (en) | 2013-10-14 | 2015-05-19 | 고려대학교 산학협력단 | Novel β-agarooligosaccharide hydrolase and enzymatic production method of 3,6-anhydro-L-galactose and galactose from agarose by using the same |
-
2016
- 2016-12-07 KR KR1020160165598A patent/KR101864800B1/en active IP Right Grant
-
2017
- 2017-11-24 US US16/467,129 patent/US11268114B2/en active Active
- 2017-11-24 CN CN201780085824.5A patent/CN110291203B/en active Active
- 2017-11-24 WO PCT/KR2017/013493 patent/WO2018105932A1/en active Application Filing
-
2022
- 2022-01-27 US US17/586,649 patent/US20220220522A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105029A1 (en) * | 1997-11-11 | 2003-06-05 | Takara Shuzo Co., Ltd. | Drugs, foods or drinks with the use of algae-derived physiologically active substances |
Non-Patent Citations (1)
Title |
---|
Lee et al. A novel agarolytic beta-galactosidase enzyme acts on agarosaccharides for complete hydrolysis of agarose into monomers. Appl and Environ Microbiol (2014), 80(19): 5965-5973). (Year: 2014) * |
Also Published As
Publication number | Publication date |
---|---|
US20200071737A1 (en) | 2020-03-05 |
US11268114B2 (en) | 2022-03-08 |
KR101864800B1 (en) | 2018-06-07 |
WO2018105932A1 (en) | 2018-06-14 |
CN110291203B (en) | 2024-01-09 |
CN110291203A (en) | 2019-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220220522A1 (en) | Method for producing anhydrous galactose derived from seaweed | |
CN108884120B (en) | Method for purifying 3, 6-anhydro-L-galactose | |
CN107988286B (en) | Method for preparing tagatose by whole-cell catalysis | |
CN109666620B (en) | Engineering strain for producing tagatose, construction method and application thereof | |
US9902983B2 (en) | Agarooligosaccharide hydrolase and method for producing 3,6-anhydro-L-galactose and galactose from agarose by using same | |
CN109234299B (en) | Method for expressing and preparing lactobiose phosphorylase | |
WO2005105991A1 (en) | Amp deaminase originating in streptomyces and utilization thereof | |
CN109706189B (en) | Preparation method of D-chiro-inositol | |
EP4324927A1 (en) | Enzyme composition for preparing ?-nicotinamide mononucleotide, and application thereof | |
EP4194544A1 (en) | Strain for producing n-acetylglucosamine, and construction method therefor and use thereof | |
CN110857444B (en) | Preparation method of scyllo-inositol | |
CN114736881B (en) | Glucose oxidase GoxM10 mutant A4D with improved acid stability and derivative mutant and application thereof | |
CN116144635A (en) | Chitinase BlChiA mutant with specific activity and acid resistance improved | |
KR101641173B1 (en) | Method for improving production yield of monomeric sugars using pretreatment of agar by buffer solution | |
JP4923631B2 (en) | Process for producing 12-aminododecanoic acid and biocatalyst used in the process | |
WO2024053959A1 (en) | Method for producing fucosylated oligosaccharide from colanic acid | |
CN112877305B (en) | Glucose dehydrogenase mutant with improved coenzyme affinity | |
CN114381446B (en) | Heat-resistant acid-resistant arabinosidase gene, and expression protein, recombinant vector, recombinant bacterium and application thereof | |
WO2022060098A1 (en) | Novel yeast strain for producing mucic acid by fermenting galacturonic acid | |
KR20100001209A (en) | Method for preparing tagatose using microorganisms which galactose uptake are repressed | |
WO2014182054A1 (en) | Recombinant microorganism metabolizing 3,6-anhydride-l-galactose and a use thereof | |
CN117737099A (en) | Heat-resistant acid-resistant xylosidase gene, protein expressed by same and application thereof | |
CN118272397A (en) | Gene combination, genetically engineered bacterium containing same and application of genetically engineered bacterium in L-lysine production | |
CN104762245B (en) | The method that the escherichia coli of acetylesterase can be expressed and prepare acetylesterase using it | |
CN115948355A (en) | NADPH oxidase mutant and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |